CA2756172C — Inhibitors of hepatitis c virus replication
Assigned to Merck Sharp and Dohme LLC · Expires 2015-11-24 · 10y expired
What this patent protects
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, he synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing CV infections and for inhibiting HCV vi…
USPTO Abstract
The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, he synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing CV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.
Drugs covered by this patent
- Zepatier (ELBASVIR) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.